Diabetic Neuropathy, Pain, and Sarcopenia: An Integrative Review of Their Convergent Pathophysiological Mechanisms and Clinical Association

Abstract

Introduction: Diabetes mellitus (DM) is an accelerator of biological aging. Diabetic peripheral neuropathy (DPN) and sarcopenia, traditionally viewed separately, are emerging as prevalent complications that share pathogenic pathways. Evidence suggests a synergistic and bidirectional interaction, where neuropathic pain is an active catalyst for musculoskeletal deterioration and disability.

Methods: A rigorous integrative review (Whittemore and Knafl framework) was performed, synthesizing heterogeneous evidence from PubMed, Scopus, and Google Scholar (2015–2025). Studies that explicitly assessed the clinical, functional, and biomolecular substrates between neuropathy, chronic pain, and muscle function in adults with diabetes were selected.

Results: The synthesis confirms a robust, clinically relevant, bidirectional association. Patients with the painful diabetic foot-and-mouth disease phenotype exhibit a significantly higher prevalence of severe sarcopenia and dynapenia (weakness), a finding that persists after adjusting for age and duration of diabetes. Pain acts as a behavioral disruptor (inducing kinesiophobia and disuse atrophy). Pathophysiologically, the convergence is based on three axes: (1) toxicity from advanced glycation end products (AGEs, such as pentosidine); (2) impaired mitochondrial bioenergetics that generates oxidative stress; and (3) pro-inflammatory neuroimmune crosstalk that perpetuates protein catabolism.

Conclusions: Neuromuscular neuropathy (NDP) is a complex and disabling neuromuscular syndrome. It is imperative to incorporate dynamometric and functional assessments into the routine screening of patients with neuropathic pain in order to intercept irreversible physical disability through early and multimodal interventions.